Glypican-5 (GPC5) has been well-characterized as a tumor suppressor in lung adenocarcinoma (LUAD); however, the functional implications of its germline mutations in cancer pathogenesis remain largely unexplored. Here, GPC5 is linked to lung adenocarcinoma.